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Abstract
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) plays an
important role in diagnosis and grading of brain tumor. Although manual DCE
biomarker extraction algorithms boost the diagnostic yield of DCE-MRI by
providing quantitative information on tumor prognosis and prediction, they are
time-consuming and prone to human error. In this paper, we propose a fully-
automated, end-to-end system for DCE-MRI analysis of brain tumors. Our
deep learning-powered technique does not require any user interaction, it yields
reproducible results, and it is rigorously validated against benchmark (BraTS’17
for tumor segmentation, and a test dataset released by the Quantitative Imaging
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Biomarkers Alliance for the contrast-concentration fitting) and clinical (44 low-
grade glioma patients) data. Also, we introduce a cubic model of the vascular
input function used for pharmacokinetic modeling which significantly decreases
the fitting error when compared with the state of the art, alongside a real-
time algorithm for determination of the vascular input region. An extensive
experimental study, backed up with statistical tests, showed that our system
delivers state-of-the-art results (in terms of segmentation accuracy and contrast-
concentration fitting) while requiring less than 3 minutes to process an entire
input DCE-MRI study using a single GPU.
Keywords:
Deep neural network, pharmacokinetic model, tumor segmentation,
DCE-MRI, perfusion, brain
1. Introduction
Dynamic contrast-enhanced imaging using magnetic resonance (DCE-MRI)
has become a widely utilized clinical tool for non-invasive assessment of the vas-
cular support of various tumors [36]. DCE analysis is performed on a time-series
of images acquired following injection of contrast material (tracer) and inves-
tigating temporal changes of attenuation in vessels and tissues. Biomarkers
extracted from such imaging have been shown to be correlated with physio-
logical and molecular processes which can be observed in tumor angiogenesis
(morphologically characterized by an increased number of micro-vessels which
are extremely difficult to image directly [36]). Therefore, DCE biomarkers can
be used to assess tumor characteristics and stage, and provide an independent
indicator of prognosis, enabling risk stratification for patients with cancer [9].
Although DCE biomarkers have been validated against many reference meth-
ods and used for assessment of a wide range of tumors, including gliomas,
glioblastomas, carcinoids, rectal, renal, and lung tumors, and many others [9],
the process of their extraction is fairly time-consuming and prone to user errors
as it requires manual segmentation of the MR data. The manual segmentation
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adversely impacts reproducibility, which is an important issue in clinical ap-
plications, particularly for longitudinal studies. In this work, we address these
problems and propose a fully-automated approach to assess brain tumor perfu-
sion from DCE-MRI without any user intervention which fits well into clinical
practice and can help clinicians decide on an optimal treatment pathway much
faster. To the best of our knowledge, such hands-free DCE analysis engines have
not been explored in the literature so far.
Input DCE-MRI 
brain study 
Brain tumor 
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Determination of 
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region 
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Figure 1: Our deep learning-powered approach for assessing brain tumor perfusion does not
require user intervention—all steps presented in the flowchart are automatic.
The contribution of this work is multi-fold. We propose an extensively vali-
dated (Section 5) system (referred to as ECONIB which unfolds to Enhancing
the diagnostic efficiency of dynamic Contrast-enhanced imaging in personalized
Oncology by extracting New and Improved Biomarkers) which requires no user
intervention for assessing brain tumor perfusion from DCE-MRI data (see its
high-level flowchart in Fig. 1). Although there were some attempts to automate
perfusion analysis in the literature [6], our system is first-to-date approach for
DCE-MRI brain imaging. To make the analysis fully automatic, we introduce:
- A deep neural network (DNN) for segmenting brain tumors from T2-
weighted sequences (Section 3.1).
- A real-time image-processing algorithm for determination of the vascular
input region from T1 VIBE sequences (Section 3.2).
- A new cubic model of the vascular input function used for pharmacokinetic
modeling whose aim is to minimize the contrast-concentration fitting error
(Section 3.3).
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- An end-to-end DCE processing pipeline which can be seamlessly inte-
grated into clinical practice.
2. Related work
The process of extraction of DCE biomarkers from brain MRI requires seg-
menting brain tumors, determining the vascular input region (most of the state-
of-the-art approaches for this task use clustering and intensive 3D processing of
brain scans [46]—we address their most important shortcoming, being the com-
putational complexity [29], by exploiting very fast image-processing routines
coupled with a 3D analysis), and performing the contrast-concentration mod-
eling and analysis. To the best of our knowledge, there are no fully-automated
approaches for the DCE analysis proposed in the literature so far, and the ex-
isting techniques suffer from lack of reproducibility and require user interaction
(hence, post-processing of DCE-MRI studies cannot be seamlessly executed just
after acquiring the scans). In this section, we summarize the state of the art
for two critical DCE-MRI processing steps—brain tumor segmentation (Sec-
tion 2.1), and pharmacokinetic modeling (Section 2.2).
2.1. Brain tumor segmentation
Approaches for brain tumor segmentation can be divided into four categories—
atlas-based, unsupervised, supervised, and hybrid. In the atlas-based approaches,
manually segmented images (atlases) are exploited to segment unseen scans [31].
These atlases model the anatomical variability of the brain tissue [28]. Atlas im-
ages are extrapolated to new frames by warping and applying various non-rigid
registration techniques. A shortcoming of such techniques is the necessity of cre-
ating large (and representative) annotated sets. It is very time-consuming and
may lead to atlases which cannot be applied to other tumors [2]. Atlas-based
approaches are thus most often used for processing images of healthy tissue [5].
Unsupervised algorithms reveal hidden structures within unlabeled data [11].
Self-organizing maps are exploited to separate healthy from pathological brain
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tissue [21]. This method has been shown to be able to highlight not only le-
sions, but also different tissue types within lesions, e.g., edema/peritumoral
infiltration or necrosis. However, lesions tend to be over-segmented. In evolu-
tionary algorithms [42], image segmentation is seen as an optimization problem,
in which pixels (or voxels) of similar characteristics are searched. It is tackled
in a biologically-inspired manner, in which a population of candidate solutions
(e.g., pixel or voxel labels) evolves in time. Such techniques commonly require
a practitioner to tune their parameters [7]. Other unsupervised algorithms in-
clude clustering-based techniques [15, 37] (also exploiting superpixels [44]), and
Gaussian mixture modeling [38].
Supervised techniques utilize manually segmented image sets to train a model.
These approaches exploit a variety of well-established engines, including decision
forests [12], conditional random fields [45], and support vector machines [18].
In [49], decision forests benefit from context-aware features. These forests are
fed with a generative model of tissue appearance elaborated using Gaussian
mixture models—the resulting model is quite lightweight, and the algorithm
does not require heavy pre-processing (there is no explicit regularization). Ap-
pearance and context-based features have also been also utilized in [30], in their
extremely randomized forests. Various deep networks have been successful in
segmentation of different kinds of medical images [19, 41], including brain tis-
sue [20, 24]. Hyperintense regions in FLAIR MRI have been segmented using
deep autoencoders in [17], where the authors performed extensive preprocessing
(skull stripping, N4 bias correction, and intensity standardization). Holistically
nested neural nets for MRI were introduced in [48]. White matter hyperin-
tensities were also segmented in [13] using several CNNs which were fed with
multiscale patches. Transfer learning was also applied for lesion segmentation
in [14]. Finally, the winning BraTS’17 algorithm utilized an ensemble of deep
neural nets [16]. Unfortunately, the authors reported neither training nor in-
ference times of their method which may easily explode for sufficiently deep
architectures, and make it inapplicable in a hospital setting.
Hybrid approaches combine methods from other categories, e.g., atlas-based
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and unsupervised [40]. They are often tailored to detect a specific lesion type.
Superpixel processing was coupled with support vector machines and extremely
randomized trees in [40]. Although the results appeared promising, the authors
did not report the computation time nor cost of their method, and did not
provide any insights into the classifier parameters. Tuning such kernel-based al-
gorithms is very difficult and expensive in practice [26], and improperly selected
parameters can easily deteriorate the classifier abilities [25]. In [33], the au-
thors pointed out that deformable models are extensively used for brain tumor
segmentation. However, such methods suffer from poor convergence to lesion
boundaries. DNNs were coupled with conditional random fields in [47].
2.2. Pharmacokinetic modeling
Modern MR scanners provide images suitable not only for qualitative as-
sessment by a reader (to reveal the structural information about the patient),
but they are also fast enough to acquire volumetric brain images in relatively
short time intervals for the contrast concentration analysis. High spatial and
temporal resolutions give a possibility to quantify the concentration of a con-
trast agent (CA) in tissues, and to assess its distribution in time in terms of a
pharmacokinetic model.
In order to apply any pharmacokinetic model to a series of MR images,
we use a mapping between the pixel intensity (in an image), and the contrast
concentration in the corresponding volume [8]. This procedure exploits the
CA’s magnetic relaxivity (specific for the used agent), the value of patient’s
haematocrit (HTC), and the pre-contrast T10 relaxation times of the scanned
tissue. The HTC value, if not provided, it is assumed to be 0.45 [8], whereas the
pre-contrast T10 relaxation times are derived from scans at different flip angles
of the magnetic field—at least two sequences acquired at two different angles
are required. For more details, see [8].
Once the mapping is established, we can obtain quantitative information
about the CA’s concentration in any MRI series within the analyzed study,
including these taken at different moments in time, revealing the kinetics of
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the CA. We interpret the spatial and temporal information in terms of the
Tofts model [43], which belongs to a group of the compartments models widely
used in the DCE analysis. Two compartments of the model represent blood
plasma and abnormal extravascular extracellular space (EES). The model allows
us to describe the CA kinetics via three tissue parameters, two of which are
independent: 1) the influx volume transfer constant Ktrans, or the permeability
surface area product per unit volume of tissue between plasma and EES; 2) the
volume of EES per unit volume of tissue ve (0 ≤ ve ≤ 1); and 3) the efflux rate
constant kep = K
trans/ve. Those parameters are commonly used as biomarkers
in quantification of a state of a tumor [1]. The model consists of a plasma volume
(vp), which is connected to a large EES, and lesion leakage space (LLS). The
LLS is assumed to be small enough to not change the total CA concentration,
and is connected to the plasma through a leaky membrane. The whole system
is assumed to be interconnected, and the CA is well-mixed with plasma. The
CA flows to EES and LLS, and it is constantly being depleted by kidneys [43].
In each moment in time, the CA concentration in LLS (Ct(t)) is in a dynamic
equilibrium, and can be derived from:
Ct(t) = K
trans · (Cp(t) ∗ exp(−kept)), (1)
where the ∗ symbol between Cp(t) and the exponential decay denotes a convo-
lution operation.
The CA’s concentration Ct(t) in LLS can be calculated in two ways: 1) by a
numerical convolution, which is computationally expensive; 2) analytically, by
exploiting a Cp(t) model and finding an analytical solution to the convolution
operation (Eq. 1). We take the latter approach, as it may smoothen out the
noise of real-life data [27], and is much faster (hence can be deployed in medical
applications).
2.2.1. Bi-exponential model of a vascular input function (VIF)
Inaccurate modeling of the VIF propagates through to the estimated tissue
parameters [32], hence an accurate model is required to obtain medical-grade
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performance. Tofts and Kermode proposed a bi-exponential model of a VIF [43]:
Cp(t) = A · exp(−αt) +B · exp(−βt), (2)
which has been widely adopted due to its simplicity. However, it assumes that
Cp(t = 0) = max(Cp), which is unrealistic, but was applicable when the scanners
had slow sampling rates. Nowadays, it is not the case, as the scanners produce
images with temporal resolution which is high enough to track the initial increase
of Cp as the contrast begins to arrive.
2.2.2. Linear model of a VIF
Orton et al. proposed a more realistic model, containing a linear term in t,
which was called the “Model 2” (bi-exponential model was called “Model 1”)
in [27], but will be referred to as a linear model in this work:
Cp(t) = A · t exp(−αt) +B ·
(
exp(−βt)− exp(−αt)). (3)
The linear model has a desired property of Cp(t = 0) = 0, which allows for mod-
eling more realistic VIF functions, while maintaining low number of parameters
(A, B, α, and β). Our experiments on a simulated benchmark dataset created
by the Quantitative Imaging Biomarkers Alliance (QIBA dataset; Section 4.1)
revealed that the linear model outperforms the bi-exponential one, yet it still
does not fit the data perfectly.
Although clinically-adopted software for pharmacokinetic modeling is lim-
ited (Tissue4D by Siemens is widely used), there exist other implementations
which are being validated against benchmark data. Smith et al. [39] devel-
oped the DCE-MRI.jl software suite, which was shown to be overcoming the
drawbacks of other DCE-MRI analysis packages (lack of portability, huge com-
putational burden, and complexity being their most important drawbacks).
3. Method
In this section, we describe the core components of ECONIB: deep learning-
powered brain tumor segmentation, determination of the vascular input region,
and pharmacokinetic modeling with the proposed VIF cubic model.
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3.1. Brain tumor segmentation
Our DNN designed for brain tumor segmentation, illustrated in Fig. 2, con-
sists of a series of blocks placed symmetrically as a contractive and expanding
path, yielding a U-shape [36]. Each block in the contractive path contains three
3 × 3 convolution layers with 64 feature maps (filters) each, followed by a rec-
tified linear unit (ReLU) activation, and a max-pooling layer with 2× 2 kernel
and stride (offset) to perform downsampling. In the expanding path, the output
of each block receives a skip connection from the depth-matched feature maps
(from the contractive path), and concatenates it to its own output, which is
upsampled and passed to a higher block. The last layer of the network is a 1×1
convolutional layer with sigmoid activation, which reduces the activation depth
to one.
Figure 2: Our U-Net-based DNN with its blocks and connections.
In this manner, high-level features, extracted in the contractive path, prop-
agate through higher resolution layers of the expanding path. In Fig. 2, we can
observe how the size of the feature map is affected by each operation, achieving
a compression of the feature space from 256× 256 to 16× 16. Residual connec-
tions between corresponding blocks in the contractive and expanding paths are
also displayed. Our DNN performs multi-scale analysis—features from the con-
tractive path are combined with the upsampled output, where a large number
of available channels allows for context propagation through high-resolution lay-
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ers. As a consequence, the expanding path is symmetric to the contractive path.
The total number of trainable parameters of our network is close to 9 · 105. In-
terestingly, our model can be applied to multi-modal processing (e.g., more than
one image modalities can be used for training and inference by stacking them
altogether in a multi-channel image)—in this work, we experimentally prove this
flexibility by segmenting brain tumors from MRI scans with three deep models
trained using one, three, and four modalities (see details in Section 5.2).
Our model is inspired by the U-Net architecture which has been already
applied for biomedical image processing [36]. There are two main differences
between the proposed DNN and the state-of-the-art U-Net—first, the number of
filters is constant at each step of the processing pipeline in our model, while it is
doubled in each deeper block in the original U-Net. Keeping a constant number
of filters reduces the number of parameters of the network, effectively lowering
its computational requirements and processing time. Second, we preserve the
shape of each feature map, which allows us to seamlessly take advantage of
the bridged connections by simply concatenating activation maps at each depth
(cropping is employed in [36]).
3.2. Determination of vascular input region
The input of our algorithm is a time series of co-registered T1 VIBE scans.
First, an arithmetic average µI is calculated for high-intensity voxels for each
volume. Voxels are considered to be high-intensity, if their intensity is above
a given threshold (we manually tuned this parameter to 0.75 of the maximum
intensity in a volume). A volume with the maximum µI is selected from the
time series as Vs. Next, Vs is cropped (Fig. 3a), and a binary mask with the
high-intensity voxels is created for Vs, yielding the volume VT . For each slice
from VT , we perform blob detection. To narrow down the search space for the
vascular input region, only the components in the lower section of the slice are
retained (Fig. 3b), which corresponds to the G, H, and I sections of the brain
in Talairach coordinates. We introduce a simple shape metric: M(S) = Ac/Ab,
where Ac is the area of a shape S, and Ab is the area of its bounding box. For a
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square shape, the metric becomes 1, whereas for a circle it is pi/4 (for elongated
and curvilinear shapes, the value of the metric will be lower). All connected
components Si for which M(Si) < pi/4 are rejected (Fig. 3c). Finally, the
binary volume VT undergoes the 3D connected-components labeling, and the
component with the largest volume is considered to contain only the voxels of
the vascular region of interest in Vs (Fig. 3d). We propagate the binary labels
from VT to all volumes (they are co-registered), and use them to measure the
contrast concentration. Importantly, our algorithm is deterministic and delivers
reproducible vascular input region determination.
3.3. Pharmacokinetic modeling
In this work, we propose a generalization of the linear model (with the aim
of minimizing the fitting error) by substituting t → tn mentioned in [27], and
putting n = 3. We have also investigated a model with a t2 term, however it
yielded more inaccurate results. We call the model with the t3 term the cubic
model. To the best of our knowledge, such model has not been used before. It
also has only four parameters (A,B, α, and β):
Cp(t) = A · t3 exp(−αt) +B ·
(
exp(−βt)− exp(−αt)). (4)
It preserves the property of Cp(t = 0) = 0, while its form allows for finding an
analytical solution to Eq. 1. Ct(t) is parametrized by six parameters: A,B, α, β
originating from a VIF, and Ktrans and kep (or ve = K
trans/kep):
Ct = K
trans
(
A ·∆−4 exp(−αt) · Ct1 +B · Ct2
)
,
Ct1 =
(− (t∆)3 − 3(t∆)2 − 6t∆− 6) exp(∆) + 6,
Ct2 =
exp(−βt)− exp(−kept)
kep − β
−exp(−αt)− exp(−kept)
kep − α , (5)
where ∆ = α− kep.
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b)
d)
a)
c)
Figure 3: Determination of the vascular input region: a) a slice in the axial plane from an
input volume, b) intensity thresholding reveals candidate regions, from which: blue regions
are rejected because they occupy an upper section of the image (above the dotted line), red
ones are rejected due to the shape irregularities, green regions are retained, c) visualization
of the volume with remained voxels grouped as connected components, d) visualization of the
volume after retaining only the largest 3D connected component.
The comparison of fits of the linear and cubic models to the QIBA data is
presented in Fig. 4. The function of the contrast concentration in time in the
vascular input region and tissue with the fitted curves is presented on panels
a) and b), respectively. The cubic model (green curve) has around an order
of magnitude lower mean square error (mse) than the fit of the linear model
(orange curve), for both plasma and tissue. This empirical evidence shows
that our proposed model of a VIF has a potential to yield higher-quality fits
required to obtain tissue parameters with high precision. The evaluation of the
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cubic model on the QIBA dataset is presented in detail in Section 5.4.
a)
b)
Figure 4: Fits of the linear model and our cubic model of the VIF to the QIBA phantom
data: contrast agent’s concentration in a) vascular input region, and in b) tissue. The data
represents tissue characterized by Ktrans = 0.10 min−1 and ve = 0.20. The mean square
error (mse) of the fit is written in bold.
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4. Data
4.1. QIBA phantom dataset
The Quantitative Imaging Biomarkers Alliance published virtual DCE phan-
tom sets that can be used for validating DCE-MRI analysis approaches1. Sev-
eral phantoms are available to validate both the procedure of mapping MR
pixel intensities to the contrast concentration values, and tissue parameters
fitting. In this work, we exploit the newest release of the QIBA set (ver-
sion 14) simulating images obtained for patients who have low cardiac out-
put, hence the patients would be expected to have lower and “broader” in-
put functions. This set consists of 661 DICOM files (each file simulating data
of one timestamp). The data in each DICOM is divided into two regions—
tissue and vascular. The tissue part is further divided into 30 (5×6) non-
overlapping patches of size 10 × 10 pixels, marking regions of tissue charac-
terized by different values of Ktrans ∈ {0.01, 0.02, 0.05, 0.10, 0.20, 0.35} min−1,
and ve ∈ {0.01, 0.05, 0.10, 0.20, 0.50}. The vascular part is placed at the bot-
tom of an image, and occupies the area of 10 × 50 pixels (Fig. 7a). Examples
of CA concentrations as a function of time in plasma and tissue for one patch
(Ktrans = 0.10 min−1 and ve = 0.20) are shown in Fig. 4a and Fig. 4b.
QIBA does not provide the reference values for the vascular region curve (the
authors do not recommend using any particular model for VIF, nor any method
to process the data). The only way to verify whether a given VIF model yields
desired performance is to test the complete solution and compare the resulting
values of the tissue parameters with those provided by QIBA—we follow this
approach in this work.
4.2. Brain tumor segmentation benchmark dataset (BraTS’17)
The performance of our DNN segmentation was evaluated over the newest re-
lease of the famous Brain Tumor Segmentation (BraTS) dataset [3, 22] (version
1https://qibawiki.rsna.org/index.php/Synthetic_DCE-MRI_Data
14
2017). The BraTS’17 set contains DCE-MRI data of 285 patients with diag-
nosed gliomas—210 high-grade glioblastomas (HGG), and 75 low-grade gliomas
(LGG). The data comes in four co-registered modalities—native pre-contrast
(T1), post-contrast T1-weighted (T1c), T2-weighted (T2), and T2 Fluid Atten-
uated Inversion Recovery (FLAIR). All the pixels have one (out of four) label:
healthy tissue, Gd-enhancing tumor (ET), peritumoral edema (ED), the necrotic
and non-enhancing tumor core (NCR/NET). As we are interested only in a bi-
nary classification (healthy/non-healthy), the classes ET, ED, and NCR/NET
are merged together into the “non-healthy” class.
4.3. Clinical DCE-MRI data
ECONIB was validated over the data collected for patients who underwent
the MR imaging with a MAGNETOM Prisma 3T system (Siemens, Erlangen,
Germany) equipped with a maximum field gradient strength of 80 mT/m, and
using a 20-channel quadrature head coil. The MRI sequences were acquired in
the axial plane with a field of view of 230×190 mm, matrix size 256×256 and 1
mm slice thickness with no slice gap. In particular, we exploited the series with
TE=386 ms, TR=5000 ms, and inversion time of 1800 ms for segmentation of
brain tumors. 44 consecutive BT LGG WHO II patients (age: 40.8±13.9 years,
23 males) were analyzed retrospectively by an experienced reader (8 years of
experience) who provided us with the ground-truth masks used for validating
our brain tumor segmentation.
5. Experimental validation
5.1. Experimental setup
We validated the pivotal ECONIB components separately over benchmark
and clinical sets to check their robustness against different data (see Sections 5.2–
5.4), and presented an example of a full end-to-end processing in Section 5.5.
ECONIB was coded in C++ and compiled with Microsoft Visual C++ 2017
(for segmentation, we used Tensorflow 1.7 over CUDA 9.0 and CuDNN 5.1).
15
The experiments ran on an Intel i7-6850K (15 MB Cache, 3.80 GHz) CPU
machine with 32 GB RAM and NVIDIA GTX Titan X GPU with 12 GB VRAM.
We trained our DNN using Nadam [10] (the initial learning rate was 10−5,
and optimizer parameters were β1 = 0.9, β2 = 0.999). The training ran until
DICE (Section 5.2.1) over the validation set did not increase by at least 0.002
in 10 consecutive epochs. For segmentation, we binarize the DNN predictions
(threshold of 0.5), and process them using the connected-components analysis
to get rid of small false-positive regions.
5.2. Validation of brain tumor segmentation
5.2.1. BraTS’17 dataset
In this experiment, we validated our DNN for brain tumor segmentation over
the BraTS’17 dataset. First, we performed a 6-fold cross-validation by splitting
the dataset into 205-40-40 (training-validation-testing) volumes (patients). We
exploited images of three modalities (FLAIR, T1c, and T2-weighted), stacked
together as channels of a single image. To evaluate the segmentation perfor-
mance, we use the DICE score which is calculated as DICE(A,B) = 2·|A∩B||A|+|B| ,
where A and B are two segmentations, i.e., manual and automated. DICE
ranges from zero to one (one is the perfect score). We report precision ηprec
(percentage of correctly classified pixels out of all the pixels classified as lesions),
and sensitivity ηtp (percentage of lesion pixels correctly classified as lesions)
elaborated by the models. They are given as ηprec =
TP
TP+FP and ηtp =
TP
FN+TP ,
where TP, FP, and FN are the numbers of true positives, false positives, and
false negatives, respectively.
The results are gathered in Table 1—the average DICE score (over the unseen
testing set) is 0.8293, and its standard deviation amounts to 0.0252 (hence,
the segmentation performance of a trained model is very high for all folds).
Consequently, both sensitivity and precision are well above 0.8, with the best
fold surpassing 0.93 in precision (with sensitivity exceeding 0.82). It shows that
our deep model delivers accurate and fairly consistent segmentation, and can
be robustly trained using different MRI data (the folds were non-overlapping).
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Table 1: The segmentation performance of our DNN over the BraTS’17 test set (in a 6-fold
cross-validation setting). The best and the worst folds are selected with respect to the DICE
score (the higher the score is, the better).
DICE Sensitivity Precision
Mean 0.8293 0.8102 0.8842
Std. Dev. 0.0252 0.0464 0.0346
Best fold 0.8664 0.8232 0.9323
Worst fold 0.7798 0.7373 0.8789
To verify the generalization capabilities of our model, we segmented the
validation set, containing data of 46 patients without the ground-truth segmen-
tation2. Additionally, we verified whether adding one additional modality (T1)
can improve the overall performance, therefore we trained two models of the
same architecture, accepting images with 3 and 4 channels. In both cases, the
dataset was split into the training and validation sets, containing 245 and 40 vol-
umes, respectively. Before feeding into the DNN, the images were z-normalized
(with the mean set to 0, and the standard deviation to 1). The details of the
training process are presented in Table 2. The number of epochs required to
converge differ, which is attributed to the stopping condition and random ini-
tialization of the network’s weights. However, the processing time of one epoch
is similar (adding one modality influences the number of parameters only in
the first layer, which is not significant with respect to the total number of the
network parameters).
The results obtained for both DNN versions (with 3 and 4 modalities) are
gathered in Table 3 (for the unseen data, the BraTS organizers report speci-
ficity as well, which is given as ηtn =
TN
TN+FP ). The mean DICE score (over
46 patients) is close to 0.83 in both cases, which is also consistent with the
mean score obtained during cross-validation. The results indicate that there is
2Our segmentations were automatically assessed by the BraTS organizers. Note that the
organizers do not report precision for the validation set.
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Table 2: The number of training epochs until reaching convergence, time required to process
a single epoch, and to train our DNN over BraTS’17 using 3 and 4 modalities.
Modalities Epochs One epoch Total
FLAIR, T1c, T2 32 791 s 7 h 02 m
FLAIR, T1, T1c, T2 24 798 s 5 h 19 m
no statistical difference between using three or four modalities (Wilcoxon test,
p < 0.01). Although the best-performing state-of-the-art segmentation method
delivers slightly better DICE (0.901) [16], the authors reported neither train-
ing nor inference times of their technique (since it was an ensemble of deep
networks, it may be inapplicable in practice). Interestingly, our algorithm not
only outperforms other techniques from the literature in terms of segmentation
accuracy, but is also much faster to learn (e.g., 3D CNNs obtained 0.822 DICE
on average and took 120 h to train [35], whereas conditional adversarial nets
obtained 0.7 DICE and required 72 h to train using parallel GPUs [34]).
Table 3: The segmentation performance over 46 BraTS’17 validation patients obtained using
our DNN trained with (a) T1c, T2, and FLAIR, and with (b) T1, T1c, T2, FLAIR.
DICE Sensitivity Specificity
Mean 0.8301 0.8391 0.9914
(a) Std. Dev. 0.1176 0.1390 0.0068
Median 0.8676 0.8752 0.9931
Mean 0.8279 0.8379 0.9917
(b) Std. Dev. 0.1159 0.1415 0.0065
Median 0.08657 0.8789 0.9930
Examples of segmented (using our model trained with three modalities)
BraTS’17 images are rendered in Fig. 5. The top row (panels a, b, and c)
shows original T2-weighted images, whereas the bottom row (panels d, e, and f)
visualize segmentations overlaid over the original images with colors indicating
the true positives (in green), false positives (red), and false negatives (blue).
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For larger tumors, the quality of our segmentation is usually higher (reaching
as high as 0.97 DICE), while for smaller and less pronounced lesions our DNN
tends to under-segment. Although the DICE score is very low in Fig. 5f (only
0.16), the tumor is appropriately detected and could be further analyzed by a
human reader (e.g., for improving segmentation if necessary). The time required
to process one volume (155 images, 240× 240 pixels each) from this set is 68 s
on a CPU, and 7 s on a GPU.
a) b) c)
e) DICE = 0.66d) DICE = 0.97 f) DICE = 0.16
Figure 5: Examples of the BraTS’17 images segmented using our DNN: a), b), and c) are
original T2-weighted images, d), e), and f) are corresponding segmentations. Green color
represents true positives, blue—false negatives, and red—false positives.
5.2.2. Clinical DCE-MRI data
In this experiment, we validated our DNN using a clinical set of 44 LGG
patients. The original scans, provided in various resolutions, were reshaped to
256 × 256 preserving the aspect ratio (symmetric zero-padding was added if
necessary). In order to assess the performance of our DNN, the data was split
into the training, validation, and testing sets containing 28, 8, and 8 patients
(without the overlaps), and a 6-fold cross-validation was performed. The train-
ing (using only T2 sequences) took 33± 6 epochs, which corresponds to 75± 15
19
minutes on average per fold while exploiting a single GPU.
Table 4: The performance of our DNN over the clinical data (in a 6-fold cross-validation
setting). The best and the worst folds are selected with respect to the DICE score.
DICE Sensitivity Specificity Precision FN rate
Mean 0.7552 0.7111 0.9996 0.8626 0.1401
Std. Dev. 0.0727 0.1164 0.0001 0.0502 0.0536
Best fold 0.8464 0.8685 0.9996 0.8296 0.1125
Worst fold 0.6254 0.5191 0.9997 0.9224 0.1779
a) b) c)
d) DICE = 0.97 e) DICE = 0.87 f) DICE = 0.46
Figure 6: Examples from our DCE-MRI set segmented using our DNN: a), b), and c) are
original T2-weighted images, d), e), and f) are corresponding segmentations. Green color
represents true positives, blue—false negatives, and red—false positives.
The results (obtained for the unseen test set) are gathered in Table 4. The
average DICE score amounts to 0.7552, which is slightly lower than the DICE
score obtained over the BraTS’17 dataset. We attribute this difference to two
factors—first, our clinical dataset contains 6 times less patients (hence, the
heterogeneity of the training set is significantly lower). Second, the segmentation
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Figure 7: QIBA (version 14) phantom set: a) a visualization of a single DICOM file (brown
frame surrounds 10 × 10 px patches of tissue characterized by a combination of different
Ktrans and ve, purple frame surrounds a 10× 50 px vascular region) alongside the results of
fitting the cubic model to this set divided by the expected values of b) Ktrans and c) ve.
labels provided by a reader may be biased, which may affect the training and give
lower generalization performance (it could be addressed by labeling a training
set by multiple readers and agreeing on the final “gold-standard” segmentation).
Nevertheless, our DNN delivers consistent segmentation across folds (standard
deviation is fairly low for all measures) which are relatively small in size, and
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do not expose high tumor shape and size variability (the worst fold with 0.6254
DICE did not encompass very small tumors which appeared in the test set).
In Table 4, we also included the FN rate (percentage of frames erroneously
annotated as “healthy” by our DNN) which shows that ECONIB agrees with a
reader in 86% of all manually-selected tumorous frames on average.
Examples of the clinical DCE-MRI images segmented using our technique
are shown in Fig. 6. Similarly, the best segmentation performance is observed
for large brain tumors, while smaller ones tend to be under-segmented (due to
a small number of such examples in the entire dataset). In Fig. 6b, we can
observe that our deep model correctly detects and segments multiple tumors in
a single frame as well. The time required to process one volume (160 images)
from this set was 77 s on a CPU, and 7 s using a single GPU on average.
5.3. Validation of the vascular input region determination
Determination of the vascular input region is an important step in extracting
the plasma curve. To verify our algorithm for this task, we calculate the root
mean square (RMS) intensity within the VIF regions for each slice separately,
and compare the values with the VIF masks segmented by a reader. Here, we
report the results obtained over our clinical data of 44 patients (see Section 5.2.2;
1995 slices contained the segmented vascular input regions in this dataset). The
average RMS difference was 2.69 · 10−5 with the standard deviation amounting
to 1.08 · 10−2, median equal to −9.40 · 10−5, and maximum of 0.0481. The
average analysis (of the entire study) takes 7.52± 2.24 ms.
5.4. Validation of pharmacokinetic modeling
To quantify the performance of our pharmacokinetic modeling, we calculated
the tissue parameters for the QIBA phantom data (for each patch), and divided
them by their expected values. The results are presented in Fig. 7(b,c), for
Ktrans and ve, respectively. Our fitting accuracy is very high for most of the sim-
ulated regions (the average error given as Ktranserror =
∣∣∣Ktransfitted −Ktranstarget∣∣∣ /Ktranstarget
equals 1.510%)—the largest error occurred for the regions with expected high
22
values of Ktrans, and low values of ve—the discrepancy reaches around 6-8%
(Fig. 7b). Analogously, the largest error (approx. 6-8%) for ve was visible in the
regions of expected high values of ve, and low values of K
trans (Fig. 7c). The
corresponding average error of the ve fitting was 2.782%. The time of fitting
3000 voxels of this QIBA set (ver. 14) was close to 5 s. A corresponding fitting
error, using the linear model (Eq. 3), was 6.501% and 5.261% for the Ktrans
and ve, respectively.
We compare the efficacy of our modeling with DCE-MRI.jl, whose authors
operated on version 6 of the QIBA dataset—their fitting errors over this set were
0.419% and 0.126% for Ktrans and ve, respectively. Importantly, DCE-MRI.jl
exploits numerical integration instead of an analytical model to approximate
the VIF, which eliminated the approximation error. However, numerical calcu-
lations are more computationally demanding than analytical approaches. De-
spite the fact that the authors implemented their algorithms in Julia, which is
claimed to be a high-level language designed for scientific computing [39], the
reported time required to fit 3000 voxels of the QIBA set was approx. 520 s
using 8 threads. The fitting error of the cubic (linear) model obtained on the
QIBA6 dataset was 5.114% (4.684%) and 3.241% (3.466%) for the Ktrans and
ve, respectively. Our system, while characterized by a worse accuracy, requires
less than 5 s to process the QIBA set (version 6), hence it is more than 100×
faster than DCE-MRI.jl. Finally, our system is also portable and can be easily
deployed using any hardware and operating system.
5.5. Illustrative example of automated DCE-MRI processing
In this section, we present an end-to-end processing example of an LGG
patient, alongside execution times of all pivotal steps of ECONIB. In Fig. 8,
we render the artifacts generated at each step of the ECONIB pipeline (the
analysis took less than 3 min using a single GPU, and 4 min without GPU). All
of them are finally embedded into a DICOM report which can be either sent
back to PACS, or analyzed locally by a reader (the process can be triggered
automatically from PACS, and does not require changing the clinical protocol).
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Figure 8: Artifacts generated at the pivotal steps of ECONIB: a) T2-weighted image, b)
segmented tumor (the meaning of the colors as before), the parameter maps for c) Ktrans,
and d) ve, contrast agent’s concentration alongside our fitting in e) plasma, and f) tissue, and
the histograms extracted from the g) Ktrans (skewness is 15.859, kurtosis is 258.021), and h)
ve (skewness is 3.571, kurtosis is -15.747) parameter maps. Automated analysis of this patient
took less than 3 min with one GPU.
In this example, we showed that ECONIB can extract quantifiable (histogram-
based [23]) features from parameter maps: kurtosis (measure of the peakedness
of the histogram) and skewness (measure of the asymmetry of the histogram).
However, to use them as biomarkers (e.g., in conjunction with Ktrans and ve),
a validation process is required (it is currently ongoing).
The time required to execute all parts of ECONIB is presented in Table 5.
This profile (consistent for all patients) shows that our brain tumor segmentation
can be greatly accelerated (40×) using a GPU. Other operations are multi-
threaded and run on CPU, hence their time is the same for both hardware
configurations. Overall, ECONIB requires less than 3 min and less than 4 min
with and without GPU, which significantly reduces the DCE-MRI analysis time,
and allows clinicians to extract reproducible results in real time.
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Table 5: Time required to accomplish selected parts of ECONIB using a single GPU and
without GPU (the CPU version). This study consists of 160 T2 images for brain tumor
segmentation, and 25 volumes (of 30 T1 images, 192 × 192 px each) acquired at different
timestamps.
ECONIB part Time on GPU [s] Time on CPU [s]
Brain tumor segmentation 2 80
VIF region determination <1 <1
Tofts model fitting 135 135
I/O, report generation 26 26
Total 163 241
6. Conclusions
We introduced a fully-automated deep learning-powered approach (ECONIB)
for the DCE-MRI analysis of brain tumor patients. The pivotal steps of ECONIB
have been thoroughly validated using both benchmark and clinical LGG data.
The experiments, backed up with statistical tests, showed that ECONIB ob-
tains state-of-the-art reproducible results (in terms of segmentation accuracy
and pharmacokinetic modeling) in a very short time which is orders of magni-
tude smaller when compared with other techniques. In particular, we showed
that:
- Our deep network for brain tumor segmentation delivers very consistent
and accurate segmentation for BraTS’17 and clinical data, and it allows
for instant processing of full T2-weighted scans (only 2 s using a single
GPU) thanks to its simplicity (it is orders of magnitude faster to train
and deploy compared with top-performing BraTS segmentation engines
known from the literature).
- Our vascular input region determination delivers robust segmentation (the
average root mean square error between the contrast concentration ex-
tracted from a segmented and ground-truth region is less than 3 · 10−5)
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in real time (processing of full T1 VIBE scans takes less than 8 ms on
average).
- Our cubic model of the VIF yields very accurate contrast-concentration fit-
ting. The mean square fitting error, obtained for the Quantitative Imaging
Biomarkers Alliance (QIBA) phantom dataset, is an order of magnitude
lower for both plasma and tissue when compared with commonly used
models. Our implementation works 100× faster compared to a validated
state-of-the-art DCE tool.
- Our DCE analysis pipeline requires less than 3 min for the end-to-end
processing (including data loading and generating DICOM reports) using
a single GPU. On a workstation which is not equipped with a GPU, the
entire processing takes only 4 min (our deep learning-powered brain tumor
segmentation is accelerated 40× using the GPU processing when compared
with its CPU version).
- ECONIB is very flexible and can extract new quantitative DCE-MRI fea-
tures (e.g., histogram- or texture-based).
Our current work is focused on validation of DCE biomarkers extracted by
ECONIB, and comparing them with the measures obtained using other well-
established software (Tissue4D, Siemens) which approximates volumes of inter-
est by simpler geometrical objects, e.g., spheres (ECONIB extracts biomark-
ers from the very segmented volumes without any additional approximation).
Once this process is finished [4], ECONIB biomarkers (including texture- and
histogram-based features) will help enhance diagnostic efficiency of the DCE-
MRI imaging and bring new value into clinical practice.
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